Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2014

View Archived Issues

Sumitomo Dainippon Pharma to jointly develop SanBio's stem cell therapy SB-623 for stroke

Proteome Sciences reports on CKId program and partnership for Alzheimer's diagnostics

HPP-971, a BACH1 inhibitor with activity in animal models of MS

Novel potent positive allosteric modulator of nAChRa7 disclosed

SignaBlok receives NIH grant to develop TREM-1 inhibitors for rheumatoid arthritis

Aethlon collaborates with Boston University on test for chronic traumatic encephalopathy

Acasti Pharma reports phase II data for CaPre

Helsinn reports phase III data for anamorelin in NSCLC patients with anorexia-cachexia

FDA grants orphan drug status to G-Pump for prevention of chronic severe hypoglycemia

Abbott acquires Kalo Pharma and CFR Pharmaceuticals to grow Latin American business

Promising clinical data for vemurafenib plus cobimetinib in BRAF mutation-positive melanoma

Allosteros Therapeutics divulges novel CaMK-II inhibitors

Roche discloses new BTK inhibitors

Novel BACE inhibitors designed at Amgen

Merck KGaA prepares novel EIF2AK4/GSK-3 inhibitors

Bristol-Myers Squibb discloses new NS5B inhibitors

Encouraging data for PD-1 inhibitor pembrolizumab in different PD-L1-positive tumors

MacroGenics and Takeda enter second DART therapeutics alliance

MedImmune presents a novel anti-isdH MAb with in vivo activity against S. aureus

Avedro resubmits NDA for corneal cross-linking system

FDA awards 15 grants through Orphan Products Grants program

Preliminary phase I data demonstrates safety of intravitreal AAV2-sFLT01 in patients with AMD

Eisai plans Aricept filing in China after successful phase III trial in severe Alzheimer's disease

Johnson & Johnson to acquire Alios BioPharma

Approval in Japan for manufacturing and distribution of ripasudil hydrochloride hydrate

Thermo Fisher Scientific, GSK and Pfizer collaborate on oncology companion diagnostics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...